TWI290051B - Particulate-stabilized injectable pharmaceutical compositions of Posaconazole - Google Patents
Particulate-stabilized injectable pharmaceutical compositions of Posaconazole Download PDFInfo
- Publication number
- TWI290051B TWI290051B TW094117524A TW94117524A TWI290051B TW I290051 B TWI290051 B TW I290051B TW 094117524 A TW094117524 A TW 094117524A TW 94117524 A TW94117524 A TW 94117524A TW I290051 B TWI290051 B TW I290051B
- Authority
- TW
- Taiwan
- Prior art keywords
- formulation
- average
- hour
- doc
- cmax
- Prior art date
Links
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical group O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 title abstract description 12
- 229960001589 posaconazole Drugs 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title description 5
- 239000000203 mixture Substances 0.000 claims abstract description 201
- 238000009472 formulation Methods 0.000 claims abstract description 181
- 208000015181 infectious disease Diseases 0.000 claims abstract description 22
- 210000004369 blood Anatomy 0.000 claims description 62
- 239000008280 blood Substances 0.000 claims description 62
- 150000003904 phospholipids Chemical class 0.000 claims description 44
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 34
- 239000002245 particle Substances 0.000 claims description 31
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 31
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 27
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 27
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 27
- 238000009826 distribution Methods 0.000 claims description 22
- 239000007853 buffer solution Substances 0.000 claims description 21
- 230000036470 plasma concentration Effects 0.000 claims description 21
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 20
- 239000000872 buffer Substances 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 16
- 241001671983 Pusa Species 0.000 claims description 16
- 238000002347 injection Methods 0.000 claims description 16
- 239000007924 injection Substances 0.000 claims description 16
- 241001465754 Metazoa Species 0.000 claims description 15
- 206010036790 Productive cough Diseases 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 15
- 208000024794 sputum Diseases 0.000 claims description 15
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims description 14
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 14
- 239000003963 antioxidant agent Substances 0.000 claims description 14
- 230000003078 antioxidant effect Effects 0.000 claims description 14
- 210000003802 sputum Anatomy 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 239000000725 suspension Substances 0.000 claims description 12
- 238000012360 testing method Methods 0.000 claims description 12
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims description 11
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 claims description 11
- 229960003942 amphotericin b Drugs 0.000 claims description 11
- 229960002303 citric acid monohydrate Drugs 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 11
- 239000004480 active ingredient Substances 0.000 claims description 10
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 9
- 239000008215 water for injection Substances 0.000 claims description 9
- 239000004471 Glycine Substances 0.000 claims description 8
- 206010030154 Oesophageal candidiasis Diseases 0.000 claims description 8
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 8
- 229940121375 antifungal agent Drugs 0.000 claims description 8
- 239000003429 antifungal agent Substances 0.000 claims description 8
- 201000005655 esophageal candidiasis Diseases 0.000 claims description 8
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 8
- 150000004682 monohydrates Chemical class 0.000 claims description 8
- 229940042880 natural phospholipid Drugs 0.000 claims description 8
- 238000002560 therapeutic procedure Methods 0.000 claims description 8
- 241000222122 Candida albicans Species 0.000 claims description 7
- 239000002111 antiemetic agent Substances 0.000 claims description 7
- 210000000988 bone and bone Anatomy 0.000 claims description 7
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 7
- 239000000473 propyl gallate Substances 0.000 claims description 7
- 235000010388 propyl gallate Nutrition 0.000 claims description 7
- 229940075579 propyl gallate Drugs 0.000 claims description 7
- 210000000115 thoracic cavity Anatomy 0.000 claims description 7
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 6
- 241000233866 Fungi Species 0.000 claims description 6
- 229940125683 antiemetic agent Drugs 0.000 claims description 6
- 239000002246 antineoplastic agent Substances 0.000 claims description 6
- 229940127089 cytotoxic agent Drugs 0.000 claims description 6
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 6
- 230000010412 perfusion Effects 0.000 claims description 6
- 150000003431 steroids Chemical class 0.000 claims description 6
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 6
- 206010007134 Candida infections Diseases 0.000 claims description 5
- 206010050346 Oropharyngeal candidiasis Diseases 0.000 claims description 5
- 230000001154 acute effect Effects 0.000 claims description 5
- 230000000844 anti-bacterial effect Effects 0.000 claims description 5
- 230000003474 anti-emetic effect Effects 0.000 claims description 5
- 201000003984 candidiasis Diseases 0.000 claims description 5
- 230000001684 chronic effect Effects 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 238000002650 immunosuppressive therapy Methods 0.000 claims description 5
- 210000004072 lung Anatomy 0.000 claims description 5
- 244000045947 parasite Species 0.000 claims description 5
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 claims description 5
- 229960002722 terbinafine Drugs 0.000 claims description 5
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims description 4
- 208000004554 Leishmaniasis Diseases 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 230000000840 anti-viral effect Effects 0.000 claims description 4
- 210000001185 bone marrow Anatomy 0.000 claims description 4
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 4
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims description 4
- 239000004568 cement Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 230000003750 conditioning effect Effects 0.000 claims description 4
- 229960003964 deoxycholic acid Drugs 0.000 claims description 4
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims description 4
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims description 4
- 238000006073 displacement reaction Methods 0.000 claims description 4
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 claims description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol Substances OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 238000001959 radiotherapy Methods 0.000 claims description 4
- 208000007442 rickets Diseases 0.000 claims description 4
- 210000001179 synovial fluid Anatomy 0.000 claims description 4
- 201000002311 trypanosomiasis Diseases 0.000 claims description 4
- 208000037026 Invasive Fungal Infections Diseases 0.000 claims description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 3
- 210000002159 anterior chamber Anatomy 0.000 claims description 3
- 210000004204 blood vessel Anatomy 0.000 claims description 3
- 229960004106 citric acid Drugs 0.000 claims description 3
- 229960004413 flucytosine Drugs 0.000 claims description 3
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims description 3
- 238000007918 intramuscular administration Methods 0.000 claims description 3
- 238000007912 intraperitoneal administration Methods 0.000 claims description 3
- 238000007913 intrathecal administration Methods 0.000 claims description 3
- 238000012423 maintenance Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000002093 peripheral effect Effects 0.000 claims description 3
- 239000001488 sodium phosphate Substances 0.000 claims description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 3
- 238000011476 stem cell transplantation Methods 0.000 claims description 3
- 230000003637 steroidlike Effects 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 3
- 229930183010 Amphotericin Natural products 0.000 claims description 2
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 claims description 2
- 241000186000 Bifidobacterium Species 0.000 claims description 2
- 208000004770 Fusariosis Diseases 0.000 claims description 2
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 claims description 2
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 229940009444 amphotericin Drugs 0.000 claims description 2
- 210000003300 oropharynx Anatomy 0.000 claims description 2
- 239000000467 phytic acid Substances 0.000 claims description 2
- 229940068041 phytic acid Drugs 0.000 claims description 2
- 235000002949 phytic acid Nutrition 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 239000013589 supplement Substances 0.000 claims description 2
- 239000002023 wood Substances 0.000 claims description 2
- 241001269524 Dura Species 0.000 claims 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims 2
- 230000002490 cerebral effect Effects 0.000 claims 2
- 210000000664 rectum Anatomy 0.000 claims 2
- 210000001215 vagina Anatomy 0.000 claims 2
- KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-naphthol Chemical compound C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 claims 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 claims 1
- 241001474374 Blennius Species 0.000 claims 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- QOTYJRJRYDWQOZ-UHFFFAOYSA-N O.C(CC(O)(C(=O)O)CC(=O)O)(=O)O.C(CC)(=O)O Chemical compound O.C(CC(O)(C(=O)O)CC(=O)O)(=O)O.C(CC)(=O)O QOTYJRJRYDWQOZ-UHFFFAOYSA-N 0.000 claims 1
- 244000227633 Ocotea pretiosa Species 0.000 claims 1
- 235000004263 Ocotea pretiosa Nutrition 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- 206010057190 Respiratory tract infections Diseases 0.000 claims 1
- 208000020456 Scedosporiosis Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- SUHOQUVVVLNYQR-MRVPVSSYSA-O glycerylphosphorylcholine Chemical compound C[N+](C)(C)CCO[P@](O)(=O)OC[C@H](O)CO SUHOQUVVVLNYQR-MRVPVSSYSA-O 0.000 claims 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 claims 1
- 229960001340 histamine Drugs 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 239000002002 slurry Substances 0.000 claims 1
- 230000001954 sterilising effect Effects 0.000 abstract description 23
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 23
- 239000008186 active pharmaceutical agent Substances 0.000 abstract description 2
- 229940102213 injectable suspension Drugs 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 description 12
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 11
- 235000006708 antioxidants Nutrition 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 8
- 238000001990 intravenous administration Methods 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 239000012453 solvate Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 241000235527 Rhizopus Species 0.000 description 6
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229940028127 histidine 3 mg/ml Drugs 0.000 description 6
- 241000223682 Exophiala Species 0.000 description 5
- 241000235395 Mucor Species 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 5
- 229960001231 choline Drugs 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 4
- 241000223600 Alternaria Species 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241001236817 Paecilomyces <Clavicipitaceae> Species 0.000 description 4
- 241000228143 Penicillium Species 0.000 description 4
- 241000223238 Trichophyton Species 0.000 description 4
- 241000223230 Trichosporon Species 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000012678 infectious agent Substances 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 229960004130 itraconazole Drugs 0.000 description 4
- -1 phosphorus lipid Chemical class 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 241001465178 Bipolaris Species 0.000 description 3
- 241000223208 Curvularia Species 0.000 description 3
- 241000223218 Fusarium Species 0.000 description 3
- 241000228402 Histoplasma Species 0.000 description 3
- 241000204031 Mycoplasma Species 0.000 description 3
- 241000233870 Pneumocystis Species 0.000 description 3
- 241001524162 Ramichloridium Species 0.000 description 3
- 241000235402 Rhizomucor Species 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 3
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 3
- 235000011130 ammonium sulphate Nutrition 0.000 description 3
- 230000002924 anti-infective effect Effects 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- 150000003851 azoles Chemical class 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 239000007972 injectable composition Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000010979 pH adjustment Methods 0.000 description 3
- 201000000317 pneumocystosis Diseases 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- 229960000999 sodium citrate dihydrate Drugs 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- PWEBUXCTKOWPCW-UHFFFAOYSA-N squaric acid Chemical compound OC1=C(O)C(=O)C1=O PWEBUXCTKOWPCW-UHFFFAOYSA-N 0.000 description 3
- 229960000984 tocofersolan Drugs 0.000 description 3
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 3
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 2
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 2
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 2
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 241000228197 Aspergillus flavus Species 0.000 description 2
- 241001225321 Aspergillus fumigatus Species 0.000 description 2
- 241000351920 Aspergillus nidulans Species 0.000 description 2
- 241000228245 Aspergillus niger Species 0.000 description 2
- 241001277988 Aspergillus sydowii Species 0.000 description 2
- 241001465318 Aspergillus terreus Species 0.000 description 2
- 241000122818 Aspergillus ustus Species 0.000 description 2
- 241000221198 Basidiomycota Species 0.000 description 2
- 241000589968 Borrelia Species 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 108010020326 Caspofungin Proteins 0.000 description 2
- 241000223203 Coccidioides Species 0.000 description 2
- 241000222511 Coprinus Species 0.000 description 2
- 241001527609 Cryptococcus Species 0.000 description 2
- 206010011732 Cyst Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- GZDFHIJNHHMENY-UHFFFAOYSA-N Dimethyl dicarbonate Chemical compound COC(=O)OC(=O)OC GZDFHIJNHHMENY-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 241000207202 Gardnerella Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000235649 Kluyveromyces Species 0.000 description 2
- 208000016604 Lyme disease Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000235048 Meyerozyma guilliermondii Species 0.000 description 2
- 241000921804 Nannizzia persicolor Species 0.000 description 2
- 208000001388 Opportunistic Infections Diseases 0.000 description 2
- 241000222051 Papiliotrema laurentii Species 0.000 description 2
- 241000235648 Pichia Species 0.000 description 2
- 241000235645 Pichia kudriavzevii Species 0.000 description 2
- 241000235070 Saccharomyces Species 0.000 description 2
- 241000222480 Schizophyllum Species 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 241000589970 Spirochaetales Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical group OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 241000224526 Trichomonas Species 0.000 description 2
- 241001609978 Trichophyton terrestre Species 0.000 description 2
- 241000222126 [Candida] glabrata Species 0.000 description 2
- 241000222295 [Candida] zeylanoides Species 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 229940091771 aspergillus fumigatus Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 208000032343 candida glabrata infection Diseases 0.000 description 2
- JYIKNQVWKBUSNH-WVDDFWQHSA-N caspofungin Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](NCCN)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@H](O)CCN)=CC=C(O)C=C1 JYIKNQVWKBUSNH-WVDDFWQHSA-N 0.000 description 2
- 229960003034 caspofungin Drugs 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 208000031513 cyst Diseases 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000004880 explosion Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 2
- 229960004884 fluconazole Drugs 0.000 description 2
- 208000024386 fungal infectious disease Diseases 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000004519 grease Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 238000009434 installation Methods 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 229960004125 ketoconazole Drugs 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 238000003921 particle size analysis Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 210000004215 spore Anatomy 0.000 description 2
- 229910021653 sulphate ion Inorganic materials 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 206010052366 systemic mycosis Diseases 0.000 description 2
- 150000003573 thiols Chemical group 0.000 description 2
- 230000009278 visceral effect Effects 0.000 description 2
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 description 2
- 229960004740 voriconazole Drugs 0.000 description 2
- PMJHHCWVYXUKFD-SNAWJCMRSA-N (E)-1,3-pentadiene Chemical compound C\C=C\C=C PMJHHCWVYXUKFD-SNAWJCMRSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- FVXDQWZBHIXIEJ-LNDKUQBDSA-N 1,2-di-[(9Z,12Z)-octadecadienoyl]-sn-glycero-3-phosphocholine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC FVXDQWZBHIXIEJ-LNDKUQBDSA-N 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- JHFAEUICJHBVHB-UHFFFAOYSA-N 1h-indol-2-ol Chemical class C1=CC=C2NC(O)=CC2=C1 JHFAEUICJHBVHB-UHFFFAOYSA-N 0.000 description 1
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 1
- 241000235389 Absidia Species 0.000 description 1
- 241001019659 Acremonium <Plectosphaerellaceae> Species 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108010064760 Anidulafungin Proteins 0.000 description 1
- 241000293035 Apophysomyces Species 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000194108 Bacillus licheniformis Species 0.000 description 1
- 241000193388 Bacillus thuringiensis Species 0.000 description 1
- 241000222490 Bjerkandera Species 0.000 description 1
- 241000222478 Bjerkandera adusta Species 0.000 description 1
- 241000335423 Blastomyces Species 0.000 description 1
- 101100326430 Caenorhabditis elegans bub-1 gene Proteins 0.000 description 1
- 241000144583 Candida dubliniensis Species 0.000 description 1
- 241000222173 Candida parapsilosis Species 0.000 description 1
- 241000222178 Candida tropicalis Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241001633123 Cladophialophora Species 0.000 description 1
- 241000222290 Cladosporium Species 0.000 description 1
- 241000223205 Coccidioides immitis Species 0.000 description 1
- 208000003495 Coccidiosis Diseases 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 102100035861 Cytosolic 5'-nucleotidase 1A Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RBNPOMFGQQGHHO-UWTATZPHSA-N D-glyceric acid Chemical compound OC[C@@H](O)C(O)=O RBNPOMFGQQGHHO-UWTATZPHSA-N 0.000 description 1
- LMKYZBGVKHTLTN-NKWVEPMBSA-N D-nopaline Chemical compound NC(=N)NCCC[C@@H](C(O)=O)N[C@@H](C(O)=O)CCC(O)=O LMKYZBGVKHTLTN-NKWVEPMBSA-N 0.000 description 1
- 241000222175 Diutina rugosa Species 0.000 description 1
- 108010049047 Echinocandins Proteins 0.000 description 1
- 241000244160 Echinococcus Species 0.000 description 1
- 241001480035 Epidermophyton Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000248325 Exophiala dermatitidis Species 0.000 description 1
- 241000223664 Exophiala jeanselmei Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000122862 Fonsecaea Species 0.000 description 1
- 241001536358 Fraxinus Species 0.000 description 1
- 244000286779 Hansenula anomala Species 0.000 description 1
- 235000014683 Hansenula anomala Nutrition 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 101000802744 Homo sapiens Cytosolic 5'-nucleotidase 1A Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010023076 Isosporiasis Diseases 0.000 description 1
- 241001480034 Kodamaea ohmeri Species 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 241000589242 Legionella pneumophila Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- 241001444195 Madurella Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- 108010021062 Micafungin Proteins 0.000 description 1
- 241001480037 Microsporum Species 0.000 description 1
- 241000893976 Nannizzia gypsea Species 0.000 description 1
- 241000549556 Nanos Species 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 208000007027 Oral Candidiasis Diseases 0.000 description 1
- 241000333181 Osmanthus Species 0.000 description 1
- 235000019082 Osmanthus Nutrition 0.000 description 1
- 241001537205 Paracoccidioides Species 0.000 description 1
- 241001057811 Paracoccus <mealybug> Species 0.000 description 1
- 241000142458 Phocoena sinus Species 0.000 description 1
- 240000008154 Piper betle Species 0.000 description 1
- 235000008180 Piper betle Nutrition 0.000 description 1
- 241000223596 Pseudallescheria Species 0.000 description 1
- 244000173166 Pyrus ussuriensis Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 241000132889 Scedosporium Species 0.000 description 1
- 241000576755 Sclerotia Species 0.000 description 1
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 1
- 241000239226 Scorpiones Species 0.000 description 1
- 241000223255 Scytalidium Species 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 241001149962 Sporothrix Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000736854 Syncephalastrum Species 0.000 description 1
- 206010042938 Systemic candida Diseases 0.000 description 1
- 241001045770 Trichophyton mentagrophytes Species 0.000 description 1
- 241000223229 Trichophyton rubrum Species 0.000 description 1
- 241000985906 Trichophyton soudanense Species 0.000 description 1
- 241001480048 Trichophyton tonsurans Species 0.000 description 1
- 241000223104 Trypanosoma Species 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 241000235013 Yarrowia Species 0.000 description 1
- 241000235015 Yarrowia lipolytica Species 0.000 description 1
- FPARPMWPRFTKNX-UHFFFAOYSA-N [H][H].[Na].[Na] Chemical compound [H][H].[Na].[Na] FPARPMWPRFTKNX-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229940098178 ambisome Drugs 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 101150039027 ampH gene Proteins 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 229960003348 anidulafungin Drugs 0.000 description 1
- JHVAMHSQVVQIOT-MFAJLEFUSA-N anidulafungin Chemical compound C1=CC(OCCCCC)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(=O)N[C@@H]2C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C2)[C@@H](C)O)[C@H](O)[C@@H](O)C=2C=CC(O)=CC=2)[C@@H](C)O)=O)C=C1 JHVAMHSQVVQIOT-MFAJLEFUSA-N 0.000 description 1
- 125000005577 anthracene group Chemical group 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- CFQGDIWRTHFZMQ-UHFFFAOYSA-N argon helium Chemical compound [He].[Ar] CFQGDIWRTHFZMQ-UHFFFAOYSA-N 0.000 description 1
- 239000005441 aurora Substances 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 229940097012 bacillus thuringiensis Drugs 0.000 description 1
- 229910001570 bauxite Inorganic materials 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229940055022 candida parapsilosis Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960003749 ciclopirox Drugs 0.000 description 1
- SCKYRAXSEDYPSA-UHFFFAOYSA-N ciclopirox Chemical compound ON1C(=O)C=C(C)C=C1C1CCCCC1 SCKYRAXSEDYPSA-UHFFFAOYSA-N 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 238000009642 citrate test Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000008355 dextrose injection Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 238000004851 dishwashing Methods 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 150000005204 hydroxybenzenes Chemical class 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 208000036732 invasive candidiasis Diseases 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- VHVPQPYKVGDNFY-ZPGVKDDISA-N itraconazole Chemical compound O=C1N(C(C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-ZPGVKDDISA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940115932 legionella pneumophila Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 229960002159 micafungin Drugs 0.000 description 1
- PIEUQSKUWLMALL-YABMTYFHSA-N micafungin Chemical compound C1=CC(OCCCCC)=CC=C1C1=CC(C=2C=CC(=CC=2)C(=O)N[C@@H]2C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C2)[C@H](O)CC(N)=O)[C@H](O)[C@@H](O)C=2C=C(OS(O)(=O)=O)C(O)=CC=2)[C@@H](C)O)=O)=NO1 PIEUQSKUWLMALL-YABMTYFHSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 229940099075 noxafil Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940100692 oral suspension Drugs 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229950004354 phosphorylcholine Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000011814 protection agent Substances 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 230000014639 sexual reproduction Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000003046 sporozoite Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57512604P | 2004-05-28 | 2004-05-28 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW200609001A TW200609001A (en) | 2006-03-16 |
| TWI290051B true TWI290051B (en) | 2007-11-21 |
Family
ID=34971355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW094117524A TWI290051B (en) | 2004-05-28 | 2005-05-27 | Particulate-stabilized injectable pharmaceutical compositions of Posaconazole |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1761247A1 (enExample) |
| JP (1) | JP2008501034A (enExample) |
| KR (1) | KR20070027564A (enExample) |
| CN (1) | CN1988887A (enExample) |
| AR (1) | AR049063A1 (enExample) |
| AU (1) | AU2005249502A1 (enExample) |
| CA (1) | CA2567803A1 (enExample) |
| IL (1) | IL179627A0 (enExample) |
| MX (1) | MXPA06013886A (enExample) |
| NO (1) | NO20066005L (enExample) |
| PE (1) | PE20060291A1 (enExample) |
| RU (1) | RU2006146555A (enExample) |
| TW (1) | TWI290051B (enExample) |
| WO (1) | WO2005117831A1 (enExample) |
| ZA (1) | ZA200609890B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060009469A1 (en) * | 2004-05-28 | 2006-01-12 | Leonore Witchey-Lakshmanan | Particulate-stabilized injectable pharmacutical compositions of posaconazole |
| RS56044B1 (sr) * | 2006-05-12 | 2017-09-29 | Christian Noe | Primena kombinovanih preparata koji sadrže antimikotike |
| EP2130540A1 (en) | 2008-06-02 | 2009-12-09 | Sandoz AG | Pharmaceutical compositions containing a crystalline form of posaconazole |
| EP2141159A1 (en) | 2008-07-03 | 2010-01-06 | Sandoz AG | A Crystalline form of posaconazole |
| EP2451805A1 (en) | 2009-07-09 | 2012-05-16 | Sandoz AG | A crystalline form of posaconazole |
| WO2011144656A1 (en) | 2010-05-19 | 2011-11-24 | Sandoz Ag | Preparation of posaconazole intermediates |
| WO2011144655A1 (en) | 2010-05-19 | 2011-11-24 | Sandoz Ag | Process for the preparation of chiral hydrazides |
| CA2798010C (en) | 2010-05-19 | 2018-09-25 | Sandoz Ag | Purification of posaconazole and of posaconazole intermediates |
| RU2585760C2 (ru) | 2010-05-19 | 2016-06-10 | Сандоз Аг | Способ получения хиральных триазолонов |
| EP3391890B1 (en) * | 2010-06-29 | 2021-08-25 | Merck Sharp & Dohme Corp. | Posaconazole intravenous solution formulations stabilized by substituted beta-cyclodextrin |
| CN108329303A (zh) | 2011-06-16 | 2018-07-27 | 桑多斯股份公司 | 制备手性化合物的方法 |
| CN103284959B (zh) * | 2012-02-22 | 2015-06-03 | 重庆圣华曦药业股份有限公司 | 泊沙康唑冻干粉针剂及制备方法 |
| CN102755628B (zh) * | 2012-07-16 | 2013-10-23 | 中国科学院微生物研究所 | 一种抗真菌的药物组合物 |
| CN102805731B (zh) * | 2012-08-22 | 2014-04-30 | 北京莱瑞森医药科技有限公司 | 泊沙康唑干混悬剂及其制备方法 |
| CN105030668B (zh) * | 2015-06-26 | 2018-03-27 | 济川药业集团有限公司 | 泊沙康唑口服混悬剂及其制备方法 |
| CN106333925B (zh) * | 2015-07-10 | 2019-06-18 | 上海美悦生物科技发展有限公司 | 一种泊沙康唑液体混悬剂及其制备方法 |
| CN105997872B (zh) * | 2016-07-08 | 2019-02-19 | 河南省立眼科医院 | 一种含有泊沙康唑的眼用纳米胶束抗真菌溶液 |
| CN110582264B (zh) * | 2017-03-26 | 2022-11-11 | V·R·斯塔福德 | 眼睑皮肤状况的处理方法 |
| CA3063115A1 (en) * | 2017-04-12 | 2018-10-18 | Vikash J. BHAGWANDIN | Compositions, packaged pharmaceuticals, and methods of using posaconazole for the sensitization of resistant tumors |
| CN110507609B (zh) * | 2018-05-21 | 2021-09-17 | 上海医药工业研究院 | 泊沙康唑口服混悬剂的制备方法 |
| CN111514146A (zh) * | 2020-04-28 | 2020-08-11 | 山西振东泰盛制药有限公司 | 含有泊沙康唑的药物组合物 |
| CN113933131B (zh) * | 2021-09-24 | 2024-01-26 | 合肥天一生物技术研究所有限责任公司 | 一种阴道微生物荧光染色液 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5091188A (en) * | 1990-04-26 | 1992-02-25 | Haynes Duncan H | Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs |
| EP2090165A3 (en) * | 2001-04-03 | 2012-03-28 | Schering Corporation | Antifungal composition with enhanced bioavailability |
-
2005
- 2005-05-27 PE PE2005000599A patent/PE20060291A1/es not_active Application Discontinuation
- 2005-05-27 CN CNA2005800248542A patent/CN1988887A/zh active Pending
- 2005-05-27 RU RU2006146555/15A patent/RU2006146555A/ru not_active Application Discontinuation
- 2005-05-27 AU AU2005249502A patent/AU2005249502A1/en not_active Abandoned
- 2005-05-27 TW TW094117524A patent/TWI290051B/zh not_active IP Right Cessation
- 2005-05-27 WO PCT/US2005/018945 patent/WO2005117831A1/en not_active Ceased
- 2005-05-27 CA CA002567803A patent/CA2567803A1/en not_active Abandoned
- 2005-05-27 AR ARP050102203A patent/AR049063A1/es not_active Application Discontinuation
- 2005-05-27 EP EP05755118A patent/EP1761247A1/en not_active Withdrawn
- 2005-05-27 MX MXPA06013886A patent/MXPA06013886A/es unknown
- 2005-05-27 KR KR1020067024996A patent/KR20070027564A/ko not_active Withdrawn
- 2005-05-27 JP JP2007515456A patent/JP2008501034A/ja not_active Withdrawn
-
2006
- 2006-11-27 IL IL179627A patent/IL179627A0/en unknown
- 2006-11-27 ZA ZA200609890A patent/ZA200609890B/xx unknown
- 2006-12-22 NO NO20066005A patent/NO20066005L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20066005L (no) | 2007-02-27 |
| EP1761247A1 (en) | 2007-03-14 |
| RU2006146555A (ru) | 2008-07-20 |
| WO2005117831A1 (en) | 2005-12-15 |
| AR049063A1 (es) | 2006-06-21 |
| ZA200609890B (en) | 2008-09-25 |
| KR20070027564A (ko) | 2007-03-09 |
| PE20060291A1 (es) | 2006-04-14 |
| CN1988887A (zh) | 2007-06-27 |
| JP2008501034A (ja) | 2008-01-17 |
| TW200609001A (en) | 2006-03-16 |
| AU2005249502A1 (en) | 2005-12-15 |
| CA2567803A1 (en) | 2005-12-15 |
| IL179627A0 (en) | 2007-05-15 |
| MXPA06013886A (es) | 2007-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI290051B (en) | Particulate-stabilized injectable pharmaceutical compositions of Posaconazole | |
| EP3400072B1 (en) | Formulations for treating bladder cancer | |
| TWI556838B (zh) | 治療關節炎之方法 | |
| CN111249260B (zh) | 包含rpl554的液体吸入制剂 | |
| CA2867343C (en) | Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration | |
| US20090226527A1 (en) | Particulate-stabilized injectable pharmacutical compositions of posaconazole | |
| JP5961551B2 (ja) | 多糖リポソーム、その調製法及びその使用 | |
| US20060009469A1 (en) | Particulate-stabilized injectable pharmacutical compositions of posaconazole | |
| JP2021535197A (ja) | 疣贅の治療 | |
| JP2025106349A (ja) | リポソームの中にカプセル化されたトリテルペノイド抗真菌薬の注射可能な組成物 | |
| BR112020002290A2 (pt) | métodos de tratamento de uma infecção fúngica em um indivíduo em necessidade do mesmo, de prevenção de uma infecção fúngica em um indivíduo, e de tratamento de infecção por candidíase vulvovaginal (vvc) em um indivíduo em necessidade do mesmo | |
| CN115089725B (zh) | 一种靶向外毛细胞并装载forskolin的纳米靶向给药系统及其制备方法与应用 | |
| HK40090116A (en) | Injectable compositions of triterpenoid antifungals encapsulated in liposomes | |
| CN1813904A (zh) | 一种制备包覆辛夷挥发油纳米脂质体滴鼻剂的方法 | |
| CN110772519A (zh) | 青藤碱或其盐在制备降低血尿酸水平、防治尿酸性肾病的药品中的用途 | |
| CN106518922A (zh) | 一种三唑类化合物及其制备方法和用途 | |
| HK40040387A (en) | Injectable compositions of triterpenoid antifungals encapsulated in liposomes | |
| HK40040387B (en) | Injectable compositions of triterpenoid antifungals encapsulated in liposomes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |